Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
Previously, many studies have been conducted on mesenchymal stem cells derived from bone
marrow or subcutaneous fat, but interest in cord blood-derived mesenchymal stem cell
treatments has been increasing recently.
In the case of cord blood as a source, the isolation of mesenchymal stem cells is easier than
bone marrow or fat tissue, and cord blood-derived mesenchymal stem cells have an advantage as
a treatment because they have faster population doubling time.
To date, no clinical research on the treatment of patients using cord blood-derived
mesenchymal stem cells has been reported in the literature, but there have already been
registered at clinicaltrials.gov and currently being conducted overseas.
In this study, we will study the safety and effectiveness of RDEB patient treatment using
cord blood-derived mesenchymal stem cells with these advantages.